Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has shared an update.
Qiagen N.V. has announced a release of voting rights as informed by the Netherlands Authority for the Financial Markets (AFM). The notification involves Barclays Plc and details various types of shares and voting rights held indirectly by Barclays entities. This announcement reflects on the distribution of shares and potential voting rights, which may influence Qiagen’s shareholder dynamics and market perception.
The most recent analyst rating on (QGEN) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in the development and sale of products for sample and assay technologies. The company focuses on providing solutions for molecular diagnostics, applied testing, academic and pharmaceutical research, and is listed on multiple stock exchanges including Frankfurt, NYSE, and SIX.
Average Trading Volume: 1,482,791
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.19B
See more data about QGEN stock on TipRanks’ Stock Analysis page.